New challenges and opportunities in nonclinical safety testing of biologics.
about
Antibody Drug Conjugates: Nonclinical Safety Considerations.Safety of PEGylated recombinant human full-length coagulation factor VIII (BAX 855) in the overall context of PEG and PEG conjugatesPreclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy.Regulatory Acceptance of Alternative Methods in the Development and Approval of Pharmaceuticals.
P2860
New challenges and opportunities in nonclinical safety testing of biologics.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
New challenges and opportunities in nonclinical safety testing of biologics.
@en
New challenges and opportunities in nonclinical safety testing of biologics.
@nl
type
label
New challenges and opportunities in nonclinical safety testing of biologics.
@en
New challenges and opportunities in nonclinical safety testing of biologics.
@nl
prefLabel
New challenges and opportunities in nonclinical safety testing of biologics.
@en
New challenges and opportunities in nonclinical safety testing of biologics.
@nl
P2093
P50
P1476
New challenges and opportunities in nonclinical safety testing of biologics.
@en
P2093
Frank-Peter Theil
Kelly Flagella
Lolke de Haan
Marque Todd
Mathias Locher
Sven Kronenberg
P304
P356
10.1016/J.YRTPH.2014.04.005
P407
P577
2014-04-19T00:00:00Z